Apolipoprotein E and Alzheimer disease

Neurology

Volumn 66, Issue 2 SUPPL. 1, 2006, Pages

  Huang, Yadong ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN; PRESENILIN 1; PRESENILIN 2; MAPT PROTEIN, HUMAN; NERVE PROTEIN; NOOTROPIC AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; CONFERENCE PAPER; DEGENERATIVE DISEASE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK ASSESSMENT; RISK FACTOR; AGED; ALLELE; ANIMAL; ARTICLE; ASTROCYTE; BRAIN; CHEMISTRY; CYTOSKELETON; DRUG DESIGN; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MACROPHAGE; METABOLISM; MOUSE; NERVE CELL; ONSET AGE; PHYSIOLOGY; TRANSGENIC MOUSE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ASTROCYTES; BRAIN; CYTOSKELETON; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPID METABOLISM; MACROPHAGES; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NOOTROPIC AGENTS; RISK FACTORS; TAU PROTEINS;

EID: 33644855143     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000192102.41141.9e     Document Type: Conference Paper

References (127)

1. Jacobsen JS. Alzheimer's disease: An overview of current and emerging therapeutic strategies. Curr Top Med Chem 2002;2:343-352.
2. Selkoe DJ. Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002;110: 1375-1381.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
4. Tang M-X, Stern Y, Marder K, et al. The APOE-ε4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-755.
5. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
6. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
7. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981;33: 11-24.
8. Weisgraber KH, Rall Jr. SC, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-9083.
9. Rall Jr. SC, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982;257:4171-4178.
10. Huang Y, Weisgraber KH, Mucke L, et al. Apolipoprotein E. Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 2004;23:189-204.
11. Mahley RW, Huang Y. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999;10:207-217.
12. Weisgraber KH, Mahley RW. Human apolipoprotein E: The Alzheimer's disease connection. FASEB J 1996;10:1485-1494.
13. Elshourbagy NA, Liao WS, Mahley RW, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 1985;82:203-207.
14. Boyles JK, Pitas RE, Wilson E, et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76:1501-1513.
15. Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148-161.
16. Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci 1996;777:166-174.
17. Diedrich JF, Minnigan H, Carp RI, et al. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 1991;65: 4759-4768.
18. Han S-H, Einstein G, Weisgraber KH, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study. J Neuropathol Exp Neurol 1994;53:535-544.
19. Bao F, Arai H, Matsushita S, et al. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Neuroreport 1996;7:1733-1739.
20. Metzger RE, LaDu MJ, Pan JB, et al. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: Implications for Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:372-380.
21. s) is preferentially associated with neuron-enriched cultures from APOE transgenic mice. Neurobiol Dis 1999;6:63-75.
22. Dekroon RM, Armati PJ. Synthesis and processing of apolipoprotein E in human brain cultures. Glia 2001;33:298-305.
23. Xu P-T, Gilbert JR, Qiu H-L, et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol 1999;154:601-611.
24. Messmer-Joudrier S, Sagot Y, Mattenberger L, et al. Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. Eur J Neurosci 1996;8:2652-2661.
25. Boschert U, Merlo-Pich E, Higgins G, et al. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 1999;6: 508-514.
26. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360.
27. LeBlanc AC, Poduslo JF. Regulation of apolipoprotein E gene expression after injury of the rat sciatic nerve. J Neurosci Res 1990;25:162-171.
28. Skene JHP, Shooter EM. Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci U S A 1983;80:4169-4173.
29. Müller HW, Gebicke-Härter PJ, Hangen DH, et al. A specific 37,000-dalton protein that accumulates in regenerating but not in nonregenerating mammalian nerves. Science 1985;228:499-501.
30. Ignatius MJ, Gebicke-Härter PJ, Skene JHP, et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A 1986;83:1125-1129.
31. Boyles JK, Zoellner CD, Anderson LJ, et al. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989;83:1015-1031.
32. Nathan BP, Bellosta S, Sanan DA, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994;264: 850-852.
33. Handelmann GE, Boyles JK, Weisgraber KH, et al. Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro J Lipid Res 1992;33:1677-1688.
34. Nathan BP, Bellosta S, Mahley RW, et al. Apolipoprotein E3- and E4-induced differences in neurite outgrowth are associated with differences in the subcellular localization of apolipoprotein E. Society for Neuroscience 1994;20 (Part 2):1033.
35. Ignatius MJ, Shooter EM, Pitas RE, et al. Lipoprotein uptake by neuronal growth cones in vitro. Science 1987;236:959-962.
36. Chen Y, Lomnitski L, Michaelson DM, et al. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 1997;80:1255-1262.
37. Slooter AJC, Tang M-X, van Duijn CM, et al. Apolipoprotein E ε4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818-821.
38. Poirier J, Baccichet A, Dea D, et al. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 1993;55:81-90.
39. Masliah E, Mallory M, Ge N, et al. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995;136:107-122.
40. -/- mice: Isoform-specific effects on neurodegeneration. J Neurosci 1999;19:4867-4880.
41. Buttini M, Akeefe H, Lin C, et al. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 2000;97:207-210.
42. Buttini M, Yu G-Q, Shockley K, et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J Neurosci 2002;22:10539-10548.
43. Raber J, Wong D, Buttini M, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. Proc Natl Acad Sci U S A 1998;95: 10914-10919.
44. Raber J, Wong D, Yu G-Q, et al. Apolipoprotein E and cognitive performance. Nature 2000;404:352-354.
45. Raber J, Bongers G, LeFevour A, et al. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci 2002;22:5204-5209.
46. Teter B, Xu P-T, Gilbert JR, et al. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J Neurosci Res 2002;68:331-336.
47. Weisgraber KH. Apolipoprotein E : Structure-function relationships. Adv Protein Chem 1994;45:249-302.
48. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
49. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E-ε2 and Alzheimer's disease: Genotype influences pathologic phenotype. Neurology 1997;48:515-519.
50. Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-166.
51. Wisniewski T, Frangione B. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-238.
52. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981.
53. Nicoll JAR, Roberts GW, Graham DI. Amyloid β-protein, APOE genotype and head injury. Ann NY Acad Sci 1996;777:271-275.
54. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002;70:708-717.
55. Kantarci OH, Hebrink DD, Achenbach SJ, et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004;62:811-814.
56. Drory VE, Birnbaum M, Korczyn AD, et al. Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001; 190:17-20.
57. Moulard B, Sefiani A, Laamri A, et al. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: Evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci 1996;139 (suppl):34-37.
58. Mirabella M, Alvarez RB, Bilak M, et al. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 1996;55:774-786.
59. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, et al. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology 2002;58:438-445.
60. Garlepp MJ, Tabarias H, van Bockxmeer FM, et al. Apolipoprotein E ε4 in inclusion body myositis. Ann Neurol 1995;38:957-959.
61. Gossrau G, Gestrich B, Koch R, et al. Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis. Eur Neurol 2004;51:215-220.
62. Paik Y-K, Chang DJ, Reardon CA, et al. Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J Biol Chem 1988;263: 13340-13349.
63. Smith JD, Melián A, Leff T, et al. Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements. J Biol Chem 1988;263:8300-8308.
64. García MA, Vázquez J, Giménez C, et al. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci 1996;16:7550-7556.
65. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998;18:69-71.
66. Simonet WS, Bucay N, Pitas RE, et al. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem 1991;266:8651-8654.
67. Simonet WS, Bucay N, Lauer SJ, et al. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem 1993;268: 8221-8229.
68. Basu SK, Brown MS, Ho YK, et al. Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci U S A 1981;78:7545-7549.
69. Shih S-J, Allan C, Grehan S, et al. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem 2000;275:31567-31572.
70. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci 2001;21:812-822.
71. Pasinetti GM, Hassler M, Stone D, et al. Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse 1999;31:278-284.
72. Vincent B, Smith JD. Astrocytes down-regulate neuronal β-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. Eur J Neurosci 2001;14:256-266.
73. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 1994;269:23403-23406.
74. LaDu MJ, Pederson TM, Frail DE, et al. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem 1995; 270:9039-9042.
75. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:2892-2897.
76. V717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 1999;96:15233-15238.
77. Holtzman DM, Pitas RE, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A 1995;92:9480-9484.
78. Hartman RE, Wozniak DF, Nardi A, et al. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp Neurol 2001;170:326-344.
79. Poirier J, Hess M, May PC, et al. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res 1991;11:97-106.
80. Beisiegel U, Schneider WJ, Goldstein JL, et al. Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem 1981;256:11923-11931.
81. Xu P-T, Gilbert JR, Qiu H-L, et al. Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci Lett 1998;246: 65-68.
82. Xu P-T, Schmechel D, Rothrock-Christian T, et al. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: Human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis 1996;3:229-245.
83. Aoki K, Uchihara T, Sanjo N, et al. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 2003; 34:875-880.
84. Dupont-Wallois L, Soulié C, Sergeant N, et al. ApoE synthesis in human neuroblastoma cells. Neurobiol Dis 1997;4:356-364.
85. Ferreira S, Dupire M-J, Delacourte A, et al. Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons. Exp Neurol 2000;166: 415-421.
86. Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 1997;4:170-186.
87. Soulié C, Mitchell V, Dupont-Wallois L, et al. Synthesis of apolipoprotein E (apoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and apoE. Neurosci Lett 1999;265:147-150.
88. Harris FM, Tesseur I, Brecht WJ, et al. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem 2004;279:3862-3868.
89. Huang Y, Liu XQ, Wyss-Coray T, et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 2001;98:8838-8843.
90. Harris FM, Brecht WJ, Xu Q, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 2003;100:10966-10971.
91. Brecht WJ, Harris FM, Chang S, et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004;24:2527-2534.
92. Ljungberg MC, Dayanandan R, Asuni A, et al. Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport 2002;13: 867-870.
93. Tolar M, Marques MA, Harmony JAK, et al. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci 1997;17:5678-5686.
94. Tolar M, Keller JN, Chan S, et al. Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate apoE neurotoxicity. J Neurosci 1999;19:7100-7110.
95. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32: 177-180.
96. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:8098-8102.
97. Cho HS, Hyman BT, Greenberg SM, et al. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation. J Neuropathol Exp Neurol 2001;60:342-349.
98. Moir RD, Atwood CS, Romano DM, et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations. Biochemistry 1999;38:4595-4603.
99. Jordán J, Galindo MF, Miller RJ, et al. Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 1998;18:195-204.
100. Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000;47:739-747.
101. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125:163-171.
102. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:11183-11186.
103. Tesseur I, Van Dorpe J, Spittaels K, et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 2000;156:951-964.
104. Tesseur I, Van Dorpe J, Bruynseels K, et al. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol 2000;157:1495-1510.
105. Harris FM, Brecht WJ, Xu Q, et al. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: Modulation by zinc. J Biol Chem 2004;279:44795-44801.
106. Nathan BP, Chang K-C, Bellosta S, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995;270:19791-19799.
107. DeMattos RB, Curtiss LK, Williams DL. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 1998;273:4206-4212.
108. DeMattos RB, Rudel LL, Williams DL. Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res 2001;42:976-987.
109. Fagan AM, Bu G, Sun Y, et al. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271:30121-30125.
110. Sun Y, Wu S, Bu G, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998;18:3261-3272.
111. Bellosta S, Nathan BP, Orth M, et al. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995;270: 27063-27071.
112. Nathan BP, Chang K-C, Bellosta S, et al. The inhibition of neurite outgrowth by apolipoprotein E4 is mediated through the low density lipoprotein receptor-related protein. Soc Neurosci 1995;21 (Part 2): 1009. Abstract.
113. Qiu Z, Hyman BT, Rebeck GW. Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J Biol Chem 2004;279:34948-34956.
114. Nilsson LNG, Arendash GW, Leighty RE, et al. Cognitive impairment in PDAPP mice depends on apoE and ACT-catalyzed amyloid formation. Neurobiol Aging 2004;25:1153-1167.
115. Lesuisse C, Xu G, Anderson J, et al. Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet 2001;10:2525-2537.
116. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994;94:860-869.
117. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92-94.
118. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-1499.
119. Martel CL, Mackic JB, Matsubara E, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J Neurochem 1997;69:1995-2004.
120. Wisniewski T, Castaño EM, Golabek A, et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145:1030-1035.
121. V717F transgenic mice. Acta Neuropathol 2000;100:451-458.
122. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 1996;14:55-61.
123. Lauderback CM, Kanski J, Hackett JM, et al. Apolipoprotein E modulates Alzheimer's Aβ(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 2002;924:90-97.
124. Mazur-Kolecka B, Frackowiak J, Kowal D, et al. Oxidative protein damage in cells engaged in β-amyloidosis is related to apoE genotype. Neuroreport 2002;13:465-468.
125. Herz J, Beffert U. Apolipoprotein E receptors: Linking brain development and Alzheimer's disease. Nat Rev Neurosci 2000;1:51-58.
126. Xu Q, Li Y, Cyras C, et al. Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J Biol Chem 2000;275:31770-31777.
127. Uchihara T, Duyckaerts C, He Y, et al. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett 1995;195: 5-8.